Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1…
<!-- Name:DistributionId Value:8749498 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:PASG
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
UPDATE – Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker…
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the…
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis…
Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregiversInterim…
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central…